| DC Field | Value | Language |
|---|
| dc.contributor.author | Koklin, I. S. | - |
| dc.date.accessioned | 2022-05-02T11:15:07Z | - |
| dc.date.available | 2022-05-02T11:15:07Z | - |
| dc.date.issued | 2015 | - |
| dc.identifier.citation | Koklin I.S. Use of selective inhibitors of arginase 2 and tadalafil in combined compensation of homocysteine-induced endothelial dysfunction / I.S. Koklin // Research Result: Pharmacology and Clinical Pharmacology. - 2015. - Vol. 1, № 1(1).- P. 13-19. - Doi: 10.18413/2500-235X-2015-1-4-15-20. - Refer.: p. 19. | ru |
| dc.identifier.uri | http://dspace.bsu.edu.ru/handle/123456789/46544 | - |
| dc.description.abstract | Use of selective inhibitors of arginase 2 in combination with tadalafil on in the course of modeling of homocysteine-induced endothelial dysfunction provided endotelio- and cardioprotective effects manifested in preventing of SED increase, adrenoreactivity, maintaining myocardial reserve and normalization of the values of biochemical markers (Total NO, expression of eNOS) | ru |
| dc.language.iso | en | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | endothelial dysfunction | ru |
| dc.subject | selective inhibitors of arginase 2 | ru |
| dc.subject | tadalafil | ru |
| dc.title | Use of selective inhibitors of arginase 2 and tadalafil in combined compensation of homocysteine-induced endothelial dysfunction | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 1, № 1
|
